APA (7th ed.) Citation

Chai, C. S., Liam, C. K., Lin, O. P., Pang, Y. K., Ho, G. F., Alip, A., . . . Poh, M. E. (2019). Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma. Oxford University Press.

Chicago Style (17th ed.) Citation

Chai, Chee Shee, Chong Kin Liam, O. Po Lin, Yong Kek Pang, G. F. Ho, A. Alip, C. K. Wong, and M. E. Poh. Afatinib Versus Gefitinib or Erlotinib in First-line Setting for Malaysia Patients with EGFR Mutant Advanced Lung Adenocarcinoma. Oxford University Press, 2019.

MLA (9th ed.) Citation

Chai, Chee Shee, et al. Afatinib Versus Gefitinib or Erlotinib in First-line Setting for Malaysia Patients with EGFR Mutant Advanced Lung Adenocarcinoma. Oxford University Press, 2019.